<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837926</url>
  </required_header>
  <id_info>
    <org_study_id>PO15019</org_study_id>
    <nct_id>NCT02837926</nct_id>
  </id_info>
  <brief_title>Comparing Health Services Interventions for the Prevention of HPV-related Cancer</brief_title>
  <acronym>CoheaHr-WP4</acronym>
  <official_title>Work Package 4: HPV Vaccination of Women in Screening Ages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      The study aims to identify global and local determinants of HPV vaccine acceptability, HPV
      vaccine uptake and compliance as well as identify logistics and programmatic issues in each
      country to offer the HPV vaccine, as a potential cervical cancer prevention strategy, to
      mid-aged women attending screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3000 women aged within the age range of 25-45 years old will be recruited; 250-300 women per
      country. These women will be identified by means of screening registry lists or screening
      clinical visits. Eligible women will receive a study questionnaire on the HPV vaccine.
      Additionally, and independently of participating in the study questionnaire, those who accept
      will get 3 HPV vaccine doses. Depending on country preferences, either Cervarix®
      (Glaxosmithkline Biologicals, S.A.) at month 0, 1 and 6 or Gardasil® (Sanofi Pasteur MSD SNC)
      at month 0, 2 and 6, will be administered.

      Safety data and HPV vaccine compliance will be assessed.

      A sub study in Spain will also analyze acceptability of HPV vaccination in a sample of women
      aged 35-40 yrs identified as poor screening attenders.

      Two independent informed consent forms will be provided; one for the study questionnaire
      participation and another for HPV vaccine administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of vaccinated patients</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>women attending for cervical cancer screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <arm_group_label>women attending for cervical cancer screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil vaccine</intervention_name>
    <arm_group_label>women attending for cervical cancer screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix®</intervention_name>
    <arm_group_label>women attending for cervical cancer screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women within the age range of 25-45

          -  attending cervical cancer screening

        Exclusion Criteria:

          -  previous history of HPV vaccine administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

